Halozyme Therapeutics (NASDAQ:HALO) issued an update on its FY 2020
Pre-Market earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.60-0.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.56. The company issued revenue guidance of $230-245 million, compared to the consensus revenue estimate of $227.01 million.Halozyme Therapeutics also updated its FY 2019
Pre-Market guidance to EPS.

Shares of Halozyme Therapeutics stock traded up $0.37 during trading hours on Tuesday, hitting $19.14. The company’s stock had a trading volume of 25,396 shares, compared to its average volume of 1,094,558. Halozyme Therapeutics has a 12 month low of $14.61 and a 12 month high of $19.73. The stock has a 50 day moving average of $18.67 and a 200 day moving average of $17.02. The company has a market capitalization of $2.80 billion, a PE ratio of -34.18 and a beta of 1.86. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.17 and a quick ratio of 2.83.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.05). The firm had revenue of $46.20 million for the quarter, compared to analyst estimates of $54.96 million. Halozyme Therapeutics had a negative return on equity of 15.76% and a negative net margin of 19.73%. The firm’s quarterly revenue was up 80.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.19) earnings per share. Equities analysts expect that Halozyme Therapeutics will post -0.42 EPS for the current year.

Several research analysts recently commented on HALO shares. BidaskClub cut Halozyme Therapeutics from a hold rating to a sell rating in a research report on Wednesday, January 1st. Zacks Investment Research raised Halozyme Therapeutics from a hold rating to a strong-buy rating and set a $18.00 price target for the company in a research report on Thursday, November 7th. Barclays raised Halozyme Therapeutics from an underweight rating to an equal weight rating and reduced their price target for the company from $17.00 to $16.00 in a research report on Tuesday, November 5th. BMO Capital Markets raised Halozyme Therapeutics from a market perform rating to an outperform rating and increased their price target for the company from $17.00 to $24.00 in a research report on Thursday, January 9th. Finally, Goldman Sachs Group started coverage on Halozyme Therapeutics in a research report on Wednesday, January 8th. They set a buy rating and a $24.00 price target for the company. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $21.67.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Further Reading: Initial Coin Offering (ICO)

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.